The objective of this meeting is to brainstorm and dialogue between international Parkinson’s disease experts and representatives of leading healthcare companies and innovative biotech startups, to better understand the evolution of the therapeutic area (met versus unmet needs, clinical trial design, derisking translational development, emerging treatment challenges) and its strategic implications for the Healthcare industry.

The topics cover the most striking unmet treatment needs of our patients with the ambition to provide a cure for Parkinson’s disease in the future. Each expert will give an interactive presentation where he will briefly review his topic, define meaningful surrogate markers for the design of future clinical trials and identify the most promising and innovative treatment avenues.
September 4, 2013

8:50 - 9:00 OPENING
P. Vigouroux, General Director of the University Hospital Bordeaux, France

MORNING SESSION (9:00 - 12:10)

9:00 - 10:00
Preclinical models of PD (caveats of current models, translational potential and the place of new models)
Chairmen: M. Vila, Barcelona, Spain and S. Hunot, Paris, France
9:00 - 9:40 Mechanisms of cellular death in PD
S. Przedborski, New York, USA
9:40 - 10:20 New animal models of PD
E. Bezard, Bordeaux, France

10:20 - 10:50 Coffee Break

10:50 - 12:10
Progress in pathophysiology, pathogenesis and genetics of PD
Chairmen: P. Burbaud and E. Bezard, Bordeaux, France
10:50 - 11:30 The contribution of genetics to the identification of new treatment targets
A. Singleton, Bethesda, USA
11:30 - 12:10 Alpha-synuclein – what makes the origami bird unfold?
G. Petsko, Waltham, USA

12:10 - 13:30 Lunch Break

AFTERNOON SESSION (13:30-16:40)

13:30 - 14:50
Unmet needs and emerging treatment challenges in PD
Chairmen: D. Devos, Lille, France and F. Tison, Bordeaux, France
13:30 - 14:10 Motor and non-motor signs
A. Yarnall, Newcastle, UK
14:10 - 14:50 Disease modification and neuroprotection
W. Olanow, New York, USA
14:50 - 15:20 Coffee Break

15:20 - 16:40
Biomarkers
Chairmen: W. Meissner, Bordeaux, France and G. Petsko, Waltham, USA
15:20 - 16:00 CSF and plasma: will we succeed?
J. Zhang, Seattle, USA
16:00-16:40 Imaging biomarkers: red herring or real possibilities?
N. Pavese, London, UK

September 5, 2013

MORNING SESSION (9:00 - 12:45)

9:00 - 11:00
New design for clinical trials
Chairmen: W. Olanow, New York, USA and J. Ferreira, Lisbon, Portugal
9:00 - 9:40 Adaptive trial design
V. Dragalin, Cambridge, USA
9:40 - 10:20 Regulatory authorities: views of the European Medicines Agency
P. Balabanov, London, UK
10:20 - 10:45 Coffee Break

10:45 - 12:05
Critical issues for the success of clinical trials
Chairmen: F. Tison, Bordeaux, France and M.C. Rodriguez-Oroz, San Sebastian, Spain
10:45 - 11:25 The interest of well-defined cohorts for clinical POC studies
W. Meissner, Bordeaux, France
11:25 - 12:05 How to improve study enrollment?
J.C. Corvol, Paris, France

12:05 - 13:30 Lunch Break

AFTERNOON SESSION (13:30 - 15:50)

13:30 - 14:50
The industry perspective
Chairman: E. Bezard, Bordeaux, France
13:30 - 14:10 Scientific issues and challenges
K. Merchant, Indianapolis, USA
14:10 - 14:50 Economic strategy and decision making
T. Blackburn, Hoboken, USA
14:50 - 15:20 Funding of clinical trials – convergence of industry, academia and patient advocacy groups
S. Chowdhury, Michael J. Fox Foundation, New York, USA
15:20 - 15:50
Innovation forecasting through bibliometrics, patent landscaping and market analysis
P. Gorry, Bordeaux, France

15:50 - 16:30 FAREWELL
16:30 End of the symposium